OncoMed Pharmaceuticals

0.8900

+0.0000

Volume:- -

Turnover:- -

Market Cap:34.43M

PE:-4.22

High:0.8900

Open:0.8900

Low:0.8900

Close:0.8900

Loading ...

Overview Company News Filings

Company Profile

Company Name:

OncoMed Pharmaceuticals

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.oncomed.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

OncoMed Pharmaceuticals, Inc., a clinical development-stage biopharmaceutical company, discovers and develops novel anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The companys product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, which is in two Phase II clinical trials for non-small cell lung cancer and pancreatic cancer patients; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer patients; vantictumab (anti-Fzd7, OMP-18R5) that is in two Phase Ib clinical trials for breast cancer and pancreatic cancer patients; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based Frizzled8 receptor or Fzd8, which is in two Phase Ib clinical trials for pancreatic and ovarian cancer patients; and brontictuzumab (anti-Notch1, OMP-52M51) targeting the Notch1 receptor, which completed Phase Ia clinical trial in solid tumor patients. It is also developing anti-DLL4/vascular endothelial growth factor (VEGF) bispecific (OMP-305B83), which is in a single-agent Phase Ia clinical trial that targets and inhibits DLL4 and VEGF for solid tumors; anti-RSPO3 (OMP-131R10), a monoclonal antibody, which is in Phase Ia/b clinical trials for solid tumor and metastatic colorectal cancer patients; Wnt small molecule inhibitors that is in preclinical testing; GITRL-Fc, a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor related protein; and undisclosed pathways. OncoMed Pharmaceuticals, Inc. has strategic alliances with GlaxoSmithKline LLC to develop therapeutic antibody product candidates targeting the Notch signaling pathway; Bayer Pharma AG for biologic and small molecule therapeutic product candidates targeting the Wnt signaling pathway; and Celgene Corporation for anti-CSC product candidates. The company was founded in 2004 and is headquartered in Redwood City, California.